Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Incorporation of prognostic and predictive factors into glioma clinical trials.

Johnson DR, Galanis E.

Curr Oncol Rep. 2013 Feb;15(1):56-63. doi: 10.1007/s11912-012-0279-z. Review.

2.

Biomarker-based trials in neuro-oncology.

Ballman KV.

Chin Clin Oncol. 2015 Sep;4(3):38. doi: 10.3978/j.issn.2304-3865.2015.09.04. Review.

3.

Correlative studies in neuro-oncology trials: should they influence treatment?

Hegi ME, Stupp R.

Curr Oncol Rep. 2006 Jan;8(1):54-7. Review.

PMID:
16464404
4.

Input of molecular analysis in medical management of primary brain tumor patients.

Idbaih A, Duran-Peña A, Bonnet C, Ducray F.

Rev Neurol (Paris). 2015 Jun-Jul;171(6-7):457-65. doi: 10.1016/j.neurol.2015.04.002. Epub 2015 May 27. Review.

PMID:
26026669
5.

Biomarkers usher in era of personalized care for malignant glioma patients.

Chakravarti A, Palanichamy K, Bell EH.

CNS Oncol. 2012 Sep;1(1):3-6. doi: 10.2217/cns.12.10. No abstract available.

6.

Molecular and genetic pathways in gliomas: the future of personalized therapeutics.

Grant R, Kolb L, Moliterno J.

CNS Oncol. 2014 Mar;3(2):123-36. doi: 10.2217/cns.14.7. Review.

PMID:
25055018
7.

Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.

Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, Reardon DA.

Curr Oncol Rep. 2011 Feb;13(1):42-9. doi: 10.1007/s11912-010-0144-x. Review.

8.
9.

Molecularly based management of gliomas in clinical practice.

Rudà R, Pellerino A, Magistrello M, Franchino F, Pinessi L, Soffietti R.

Neurol Sci. 2015 Sep;36(9):1551-7. doi: 10.1007/s10072-015-2332-9. Epub 2015 Jul 21. Review.

PMID:
26194534
10.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

11.

Clinical trials for predictive medicine: new challenges and paradigms.

Simon R.

Clin Trials. 2010 Oct;7(5):516-24. doi: 10.1177/1740774510366454. Epub 2010 Mar 25.

12.

Biomarkers classification and therapeutic decision-making for malignant gliomas.

Olar A, Aldape KD.

Curr Treat Options Oncol. 2012 Dec;13(4):417-36. doi: 10.1007/s11864-012-0210-8.

PMID:
22956341
13.

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA.

Neuro Oncol. 2001 Jan;3(1):46-54.

14.

Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.

Wen PY, Reardon DA.

Nat Rev Neurol. 2016 Feb;12(2):69-70. doi: 10.1038/nrneurol.2015.242. Epub 2016 Jan 18. Review. No abstract available.

PMID:
26782337
15.

On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success.

Gilbert MR.

Curr Oncol Rep. 2013 Feb;15(1):24-6. doi: 10.1007/s11912-012-0282-4.

PMID:
23180217
16.

[OMICS and biomarkers of glial tumors].

Idbaih A.

Rev Neurol (Paris). 2011 Oct;167(10):691-8. doi: 10.1016/j.neurol.2011.07.007. Epub 2011 Sep 1. Review. French.

PMID:
21889780
17.

IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.

Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, Yan W, You Y.

Oncotarget. 2015 Oct 6;6(30):30232-8. doi: 10.18632/oncotarget.4920.

18.

Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.

Lukas RV, Amidei C.

Tumori. 2014 May-Jun;100(3):358-62. doi: 10.1700/1578.17228. Review.

PMID:
25076251
19.

[Prognostic and predictive factors for gliomas in adults].

Frenel JS, Botti M, Loussouarn D, Campone M.

Bull Cancer. 2009 Apr;96(4):357-67. doi: 10.1684/bdc.2008.0776. Review. French.

20.

Molecular neuro-oncology: a forward-looking perspective.

Wick W, O'Neill T.

CNS Oncol. 2013 Nov;2(6):491-3. doi: 10.2217/cns.13.47.

Supplemental Content

Support Center